Form 4: Macrogenics Director Converts RSUs to Common Stock

Macrogenics Director Scott Koenig converted 15,831 restricted stock units into common stock, increasing his direct ownership.

Summary

• Scott Koenig, a Director at Macrogenics Inc. (MGNX), converted 15,831 Restricted Stock Units (RSUs) into common stock.
• This transaction occurred on February 8, 2026, as part of a scheduled vesting event.
• Following this conversion, Koenig directly owns 846,075 shares of Macrogenics common stock.
• He also retains beneficial ownership of 15,832 derivative securities, specifically Restricted Stock Units.
• The RSUs convert into the company's common stock on a one-for-one basis.
• The original grant of 95,000 restricted stock units was made on February 8, 2024, with a vesting schedule that included portions vesting after one year, on August 13, 2025, and in two equal installments on the anniversary of the grant date.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it reflects a director's continued ownership and participation in the company's equity, which can signal confidence, without introducing new material information.

Positives

• Director Scott Koenig increased his direct beneficial ownership of Macrogenics common stock by 15,831 shares, which can signal continued confidence in the company's future.
• The conversion is a routine event, part of a pre-established vesting schedule for RSUs granted on February 8, 2024, indicating adherence to compensation plans.

Future Outlook

The filing indicates that 15,832 restricted stock units remain outstanding and are expected to vest in a future installment on the anniversary of the grant date (February 8, 2027).

Industry Context

StockSavvy.ai notes that routine insider transactions like RSU conversions are common in the biotechnology industry, often reflecting standard executive compensation structures designed to align management's long-term interests with those of shareholders.

Comparison to Industry Standards

• This RSU vesting and conversion is a standard practice for executive compensation across various industries, including biotech, and aligns with typical equity incentive plans.
• The one-for-one conversion ratio of RSUs to common stock is a common structure for such awards.

Stakeholder Impact

• Shareholders: Increased direct ownership by a director may be viewed positively as it aligns insider interests with shareholder value.
• Employees: Reflects standard equity compensation practices within the company.

Next Steps

• The remaining 15,832 restricted stock units are expected to vest in a future installment on the anniversary of the grant date (February 8, 2027).

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled conversion of restricted stock units by a director, which is a standard compensation event and does not provide new fundamental information to warrant a change in investment thesis. It indicates continued insider ownership but no significant new bullish or bearish signals.

Keywords

Macrogenics, MGNX, Scott Koenig, Form 4, insider transaction, RSU conversion, common stock, director, beneficial ownership